Anemia in patients on combined androgen block therapy for prostate cancer.
Year: 2004
Type: article
Abstract: AIM: To study the effect of combined androgen block therapy on hemoglobin and hematocrit values in patients with prostate cancer. METHODS: One hundred and thirty-six patients with adenocarcinoma of prostate were treated with combined androgen block (orchiectomy and flutamide 250 mg, tid). Complete blood counts were determined before and after 1, 2, 3, 6, 9 and 12 months of therapy. RESULTS: The hemoglobin and hematocrit levels declined significantly in all patients and at all the time points after treatment (P<0.05). CONCLUSION: Prostate cancer patients treated with combined androgen block would develop obvious anemia. Recombinant human erythropoietin can be used to treat patients with severe anemia.
Source: PubMed
Institutions: Jiangsu Province Hospital, Nanjing Medical University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W83624850